News 
Market Data 
Discover
Replies to post #10549 on Curative Biotechnology Inc (CUBT)
CTYX New CEO is a Harvard Business Graduate. He founded Sunmed Advisors and also NobelPharma which has 269 employees.
PAUL M. MICHAELS
For the past two decades, Mr. Michaels has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead, to name just a few.
Paul has also provided financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead (formerly Nexstar Pharmaceuticals). Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market in addition to other corporate responsibilities that included overall evaluation of corporate asset values. Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder,he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
Paul began his career as Co-Founder, Executive Vice President and Board Member of Global Capital Group, a publicly traded corporate finance firm on Wall Street where he structured, financed and advised transactions in multiple spaces utilizing a variety of financial vehicles including private placements and Initial Public Offerings.
He received his Bachelor’s degree from Tulane University and completed an HBX program from Harvard.
03/04/20 1:35 PM
03/04/20 2:14 PM
03/06/20 10:09 PM
03/06/20 10:40 PM
Current Clients & Projects
Small molecule drug that penetrates the blood-brain barrier and activates PKC enzymes, resulting in improved synaptic function, new synapse formation, repair of damaged synapses, and prevention of neuronal death in Alzheimer’s.
Neurology Phase 2 Product
